



European Association of Urology



## Letter to the Editor

**Reply to Byung Kwan Park's Letter to the Editor re: Baris Turkbey, Andrew B. Rosenkrantz, Masoom A. Haider, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol 2019;76:329–40**

We thank Dr. Park for his interest in our article [1] and for raising several key considerations. We recognize the importance of these nuances of Prostate Imaging-Reporting and Data System (PI-RADS) v2.1 and appreciate having this opportunity to clarify certain aspects of the system. First, for the example of a 2-cm transition zone (TZ) lesion with a T2-weighted imaging (T2WI) score of 3 and a diffusion-weighted imaging (DWI) score of 5, the overall PI-RADS assessment category in PI-RADS v2 and v2.1 would be 4. In this case, the DWI score of 5 would elevate the score on T2WI to a final category of 4. The size of >1.5 cm would not further elevate the final category to 5 from an initial score of 3 on T2WI. That is, the score for a lesion would only be elevated a single time, and a size of >1.5 cm would only serve to elevate the lesion category if the lesion were to otherwise receive an upfront score of 4 on T2WI. Regarding the question about a TZ lesion showing definite extraprostatic extension, in both v2 and v2.1 such a lesion would receive a score of 5 on T2WI, and thus an overall PI-RADS assessment category of 5, on the basis of this definite extraprostatic extension. For both of the above aspects of PI-RADS v2.1, we note that whether a lesion receives a PI-RADS assessment category of 4 or 5, management will usually entail a targeted biopsy. Finally, regarding the newly introduced component in PI-RADSv2.1 of a DWI score of 4 or 5 elevating TZ lesions with a T2WI score of 2 to an overall assessment category of 3, Dr. Park's letter does not note a specific concern or point of confusion. Nonetheless, we note that in such instances, the lesion score would only be elevated a single time to a final category of 3, and would not

be raised further for a T2WI score of 2. As was the case for PI-RADS v2 when it was first released several years ago, the revised decision rules in v2.1 have not yet undergone rigorous assessment, and we welcome data from the prostate imaging community regarding the system updates.

**Conflicts of interest:** Andrew B. Rosenkrantz has received royalties from Thieme Medical Publishers. Jeffrey C. Weinreb is a medicolegal consultant for Bayer Healthcare Pharmaceuticals. The remaining authors have nothing to disclose.

## Reference

- [1] Turkbey B, Rosenkrantz AB, Haider MA, et al. Prostate Imaging Reporting and Data System version 2.1: 2019 update of Prostate Imaging Reporting and Data System version 2. *Eur Urol* 2019;76:329–40.

Andrew B. Rosenkrantz<sup>a,\*</sup>  
Baris Turkbey<sup>b,\*</sup>  
Jelle Barentsz<sup>c</sup>  
Jeffrey C. Weinreb<sup>d</sup>

<sup>a</sup>Department of Radiology, NYU Langone Medical Center, New York, NY, USA

<sup>b</sup>Molecular Imaging Program, National Cancer Institute, Bethesda, MD, USA

<sup>c</sup>Department of Radiology and Nuclear Medicine, Radboudumc, Nijmegen, The Netherlands

<sup>d</sup>Department of Radiology, Yale School of Medicine, New Haven, CT, USA

\*Corresponding authors. Molecular Imaging Program, National Cancer Institute, 10 Center Drive, Bethesda, MD 20892, USA. Tel. +1 240 7606112; Fax +1 301 4801434. E-mail address: turkbey@mail.nih.gov (B. Turkbey).

Department of Radiology, NYU Langone Health, 660 First Avenue, New York, NY 10016, USA. Tel. +1 212 2630232. E-mail address: andrew.rosenkrantz@nyulangone.org (A.B. Rosenkrantz).

E-mail addresses: [andrew.rosenkrantz@nyulangone.org](mailto:andrew.rosenkrantz@nyulangone.org) (A.B. Rosenkrantz), [turkbey@mail.nih.gov](mailto:turkbey@mail.nih.gov) (B. Turkbey).

May 23, 2019

